Lessons from DRCR.net Protocol T

In this 1-Minute Video, Dr. John Wells summarizes the results from the DRCR.net Protocol T clinical trial comparing aflibercept (Eylea), ranibizumab (Lucentis) and bevacizumab (Avastin) for center-involved macular edema. Overall, all 3 treatments improved vision. However, Dr. Wells recommends that physicians should choose an agent based on baseline vision. Patients with baseline vision between 20/32 to 20/40 responded similarly to all 3 agents. However, aflibercept was the best at improving vision for patients with baseline vision of 20/50 or worse.

Relevant Financial Disclosures: Dr. Wells receives grant support from and is a consultant for Genentech. He also receives grant support from Regeneron.